title: [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].
abstract: Teriparatide is a peptide with 34 amino acids that corresponds to N-terminal portion of parathyroid hormone (PTH) . Teriparatide is the only anabolic agent currently available and prevent fractures by increasing bone mass and improving bone architecture. PTH and bone turnover are reported to be low in some patients with type 2 diabetes and chronic kidney disease. For these patients, it seems to be theoretically reasonable to use teriparatide. However, it has not been shown that teriparatide is more effective for patients with low bone turnover than other subjects.
authors.affiliation: Division of Nephrology & Endocrinology, Department of Medicine, University of Tokyo Hospital, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Fukumoto
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D008019:Life Style; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide